Purchase this article with an account.
Carlos A Abdala, Maria A. Izquierdo, cesar atencia; Laser Alone in Pre-Threshold Retinopathy of prematurity (ROP) and Combination Therapy in Threshold ROP: Anatomics results. Invest. Ophthalmol. Vis. Sci. 2016;57(12):6274.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe the anatomic results after treatment with Laser alone in infants with Pre-Threshold ROP and a Combination Therapy of Laser and Intravitreal Injection of Bevacizumab in infants with Threshold ROP in Barranquilla – Colombia between 2008 and 2014
Materials and Methods: Cross sectional study with case control analysis. Data collected from secundary sources. Inclusion criteria: Infants ≤32 weeks and / or ≤ 1750 gr. Patients with incomplete medical records were excluded. The variables were: gestational age, birth weight, gender, chronological age, twin pregnancy, sepsis, oxygen, respiratory distress, perinatal surgeries, intraventricular hemorrhage, blood transfusions, distribution of ROP by stage, areas and type, distribution according to treatment and the relationship with weight and gestational age. Laser photocoagulation treatment in patients with Pre-Threshold ROP Type 1 and a Combined Treatment of Laser and Intravitreal Bevacizumab in patients with Threshold Disease was performed. Pogression or involution of ROP after treatment was also evaluated
We studied 1038 eyes. Pre-Threshold ROP Type 1 was diagnosed in 88 eyes with a prevalence of 8.7% and Threshold ROP was diagnosed in 80 eyes with a prevalence of 7.7%. The largest proportion of patients with ROP by gestational age were ranged from 27 to 28 weeks group with 37. 8%, followed by range of 29-30 weeks . 32.9% of patients with ROP were in 751-1000 g group, followed by 1001-1250 g group with 30.7%. A statistically significant difference was found between low birth weight, gestational age between 26 and 28 weeks, oxygen and respiratory distress. 96.6% of Pre-Threshold ROP infants treated with Laser had a completed resolution of ROP. 3.4% required a Rescue Therapy 15 days after initial treatment with Intravitreal Inyection of Bevacizumab (0.65 mg/0.05 cc) and a second Laser treatment. 93.7% of Threshold ROP infants treated with a combined treatment of Laser and Intravitreal Bevacizumab Inyection had a completed resolution of ROP. 73% of infants required a single dose of intravitreal bevacizumab and 26.6% required a second dose.
Laser alone in Pre-Threshold ROP and a Combination Theraphy of Laser and Intravitreal Bevacizumab in Threshold ROP showed to be an effective treatment to obtain the involution in active forms of ROP
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only